There is excitement in the pharma space, but with the Nifty Pharma index’s price-to-earnings (PE) valuation multiple at 38, the sector is fully priced for its growth outlook. Based on our scientific investing framework, we recommend taking some profits rather than increasing exposure.”
-Ashwini Shami (EVP and Portfolio Manager – OmniScience Capital) with Moneycontrol